STVN trades 88.5% below Wall Street's consensus target of $25.58.
Last 12 months price action with 12-month analyst target path
The base valuation assumes STVN achieves its forward estimates and maintains a stable P/E multiple of 22.3x. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Stevanato Group S.p.A. (STVN) has a Wall Street consensus price target of $25.58, based on estimates from 9 covering analysts. With the stock currently trading at $13.57, this represents a potential upside of +88.5%. The company has a market capitalization of $3.70B.
Analyst price targets range from a low of $17.50 to a high of $33.00, representing a 61% spread in expectations. The median target of $26.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, STVN trades at a trailing P/E of 23.8x and forward P/E of 22.3x. The forward PEG ratio of 1.88 indicates reasonable valuation for growth. Analysts expect EPS to grow +18.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $15.09, with bear and bull scenarios of $9.51 and $19.88 respectively. Model confidence stands at 51/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 APOGApogee Enterprises, Inc. | $955M | $45.77 | $61.33 | +34.0% | Hold | 13.3x | 6 |
 BCPCBalchem Corp | $5.6B | $174.43 | $212.50 | +21.8% | Buy | 31.8x | 10 |
 BDXBecton, Dickinson and Company | $58.4B | $211.88 | $200.57 | -5.3% | Buy | 16.7x | 34 |
 WSTWest Pharmaceutical Services, Inc. | $28.1B | $399.81 | $427.43 | +6.9% | Buy | 42.3x | 17 |
 AVTRAvantor, Inc. | $10.5B | $15.47 | $14.55 | -5.9% | Hold | 18.9x | 26 |
 AZTAAzenta, Inc. | $1.8B | $39.16 | $43.00 | +9.8% | Buy | 123.1x | 12 |
 PFEPfizer Inc. | $167.5B | $29.39 | $31.13 | +5.9% | Hold | 9.8x | 40 |
 LLYEli Lilly and Company | $1.3T | $1354.00 | $1445.12 | +6.7% | Buy | 38.3x | 46 |
 NVONovo Nordisk A/S | $179.0B | $40.31 | $42.33 | +5.0% | Buy | 1.8x | 39 |
 AMGNAmgen Inc. | $248.5B | $460.42 | $415.58 | -9.7% | Buy | 19.6x | 41 |
Quick answers to the most common questions about buying STVN stock.
The consensus Wall Street price target for STVN is $25.58, representing 88.5% upside from the current price of $13.57. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
STVN has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $25.58 implies 88.5% upside from current levels.
STVN trades at a forward P/E of 22.3044x, representing a moderate valuation. With analysts targeting $25.58 (88.5% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $33 for STVN, while the most conservative target is $17.5. The consensus of $25.58 represents the median expectation. Our quantitative valuation model projects a bull case target of $20 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
STVN is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 4 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month STVN stock forecast based on 9 Wall Street analysts shows a consensus price target of $25.58, with estimates ranging from $17.5 (bear case) to $33 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $15, with bear/bull scenarios of $10/$20.
Our quantitative valuation model calculates STVN's fair value at $15 (base case), with a bear case of $10 and bull case of $20. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 51/100.
STVN trades at a forward P/E ratio of 22.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 23.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on STVN, with a "Buy" consensus rating and $25.58 price target (88.5% upside). 5 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
STVN analyst price targets range from $17.5 to $33, a 61% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $25.58 consensus represents the middle ground. Our model's $10-$20 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.